Table 1.
Characteristics of the Studies That Evaluated Fracture Frequency and Fracture Risk in People Living With HIV
| Author | Year | Study design | Site | Age (years) | Male gender (%) | HAART (%) | Outcome |
|---|---|---|---|---|---|---|---|
| Arnsten et al.6 | 2007 | Cohort | USA | 55 | 100 | – | Fracture incidence |
| Battalora et al.7 | 2016 | Cohort | USA | 43 (36–49) | 83.2 | 96.1 | Fracture incidence |
| Bedimo et al.8 | 2012 | Cohort | USA | 18–70+ | 98 | 69.4 | Fracture incidence |
| Borges et al.9 | 2017 | Cohort | Europe, Argentina, Israel | 41 | 75 | 90 | Fracture incidence |
| Collin et al.10 | 2009 | Cohort | France | 36 | 77.2 | 100 | Fracture incidence |
| Gallant et al.11 | 2004 | RCT | South America, Europe, USA | 36 | 73.9 | 100 | Fracture incidence |
| Gedmintas et al.12 | 2017 | Cohort | USA | 43 | 72 | 100 | Fracture incidence |
| Guaraldi et al.13 | 2011 | Case‐control | Italy | 46 | 63 | – | Risk of fracture |
| Güerri‐Fernandez et al.14 | 2013 | Cohort | Spain | 50 | 75.3 | – | Risk of fracture |
| Hansen et al.15 | 2012 | Cohort | Denmark | 37(31–45) | 76 | 78 | Risk of fracture |
| Hasse et al.16 | 2011 | Cohort | Swiss | 45 (39–51) | 70.8 | 85.1 | Fracture incidence |
| Kurita et al.17 | 2014 | Cohort | Japan | 15–81 | 92.8 | 65.9 | Fracture incidence |
| Mazzotta et al.19 | 2015 | Cross‐sectional | Italy | 44 | 70.6 | 79.7 | Fracture prevalence |
| Martin et al.18 | 2009 | RCT | Australia | 45 | 97.5 | 100 | Major fracture incidence |
| Mundy et al.20 | 2012 | Case‐control | USA | 40 | 71 | 50 | Risk of fractures in HIV‐treated people |
| Peters et al.21 | 2013 | Case‐control | UK | 46 | 60 | 85 | Risk of fractures |
| Prieto‐Alhambra et al.22 | 2014 | Case‐control | Denmark | 43 | 48.2 | – | Risk of fractures |
| Prior et al.23 | 2007 | Case‐control | Canada | 38 | 100 | 72.5 | Risk of fractures |
| Sharma et al.24 | 2015 | Cohort | USA | 40 (34–46) | 0 | 63 | Risk of fractures |
| Short et al.25 | 2014 | Cross‐sectional | UK | 45 (38–51) | 100 | 78 | Fracture prevalence |
| Triant et al.26 | 2008 | Case‐control | USA | 20–79 | 65.2 | – | Risk of fractures |
| Womack et al.27 | 2011 | Cohort | USA | 53 (48–61) | 100 | 75 | Increased risk of fractures |
| Yang et al.28 | 2012 | Cohort | Taiwan | <20–>60 | 76.9–90.1 | – | Orthopedic injury incidence |
| Yin et al.29 | 2012 | Cohort | USA | 39 (33–45) | 83 | 99.7 | Fracture incidence |
| Yin et al.30 | 2010 | Cross‐sectional | USA | 56 | 0 | 79.3 | Prevalence of fractures |
| Yong et al.31 | 2011 | Case‐control | Australia | 49.8 | 88.5 | 80.3 | Fracture incidence |
| Young et al.32 | 2011 | Cohort | USA | 40 (34–46) | 79 | 72.7 | Fracture incidence |
HIV = human immunodeficiency virus; HAART = highly active antiretroviral therapy; – = information not given; RCT = randomized clinical trial; ICD = International Code of Diseases.